START is a pilot program newly launched jointly by the FDA CDER and CBER divisions to further accelerate the development of novel drug and biological p...
Thermo Fisher Scientific, a global leader in scientific research solutions, has introduced cutting-edge solutions aimed at enhancing research wor...
Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs has signed a Memorandum of Understanding (MOU) with Juli...
Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo®(nivolumab) in combination with cisplatin and gemcitabine ...
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has launched its M...
lifespin GmbH, a pioneer in health status detection software, has teamed up with Acıbadem University (ACU) and Acıbadem Healthcare Group (AHG) to launc...
OSE Immunotherapeutics and Boehringer Ingelheim announced a major expansion of their partnership. Two new projects to develop first-in-class treatments wi...
YGION Biomedical GmbH, a company dedicated to developing individualized neoantigen-based cancer vaccines, today announced the completion of a Series A fina...
Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more eff...
Google DeepMind and Isomorphic Labs have unveiled AlphaFold 3, a groundbreaking AI model poised to rewrite the rulebook on molecular biology and redefine t...
Agreement provides patients with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, fro...
Ribobay Pharma, a prominent Chinese biopharmaceutical contract research, development, and manufacturing organization (CRDMO), in conjuncti...
QIAGEN announced a cooperative research and development agreement (CRADA) with the U.S. Federal Bureau of Investigation (FBI) to develop a novel test for i...
- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform - - Phase 1 first-i...
© 2025 Biopharma Boardroom. All Rights Reserved.
